SCHEMBL23901410

SCHEMBL23901410

CC1(CCC(=O)N2CCN(c3ccccc3)CC2)NC(O)NC1=O

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 17/20 0.67
▸ MMP2 P08253 8/20 0.67
▸ MMP13 P45452 3/20 0.54
▸ ADAMTS4 O75173 2/20 0.54
▸ MAPT P10636 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ ADAM17 P78536 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HTR1A P08908 1/20 0.49
▸ HTR7 P34969 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23901205 0.89 ADAMTS5 (0.70) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL23901420 0.88 ADAMTS5 (0.71) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL19996698 0.86 ADAMTS5 (0.69) ADAMTS5MMP2ADAM17
SCHEMBL19996668 0.85 ADAMTS5 (0.59) ADAMTS5MMP2MAPTLMNAMEN1
SCHEMBL23901339 0.84 ADAMTS5 (0.72) ADAMTS5MMP2ADAMTS4ADAM17
SCHEMBL25948111 0.83 ADAMTS5 (0.70) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL19709343 0.82 ADAMTS5 (0.59) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL19996688 0.81 ADAMTS5 (0.71) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL19709538 0.81 ADAMTS5 (0.58) ADAMTS5MMP2MMP13ADAMTS4ADAM17
SCHEMBL17871441 0.81 ADAMTS5 (1.00) ADAMTS5MMP2MMP13ADAMTS4ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2021-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS ADAMTS1, ADAMTS5, ADAMTS7 ADAMTS5 2/4885MMP2 53/4885MMP13 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback